about
Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropismSoluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing EpitopesPreclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog.Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.Human cytomegalovirus encodes a highly specific RANTES decoy receptor.Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease.Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease.A heterogeneous nuclear ribonucleoprotein A/B-related protein binds to single-stranded DNA near the 5' end or within the genome of feline parvovirus and can modify virus replication.Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.Genetic Stability of Parainfluenza Virus 5-Vectored Human Respiratory Syncytial Virus Vaccine Candidates after In Vitro and In Vivo Passage.Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates.A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism.A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines.Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirusModified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infectionA Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural InfectionA potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoproteinPhase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative SubjectsNeutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas
P50
Q34212879-EF5C9DEE-2AFA-41FA-8EFF-1EC805DBBC2DQ35783065-6C298A6F-8F6A-4264-B2F6-0257A89E4335Q37197051-E1F8477B-7BEC-430D-8A21-C7CD2B8456E6Q37355125-B7AD064C-BD31-4315-85BE-712BD1775639Q37409489-F41932BD-680B-40E8-A3C1-53BB5F7A41F4Q37692751-6C70BC7A-77EC-4C20-AF97-97AA3491E5C1Q37707461-48064027-6D72-4EE7-908B-6FD24F7684B0Q38196225-4BEF9240-8D66-4C28-8D5D-29416B9E9633Q38200419-6CF12C2D-1B86-4E01-93DD-75FE1CCC314CQ38321892-65AD9033-804C-473E-922F-34B3F7FCA673Q38708710-5817267B-5D0F-41CB-9457-ACF865F1E42CQ38905050-AFFD51A9-D9AA-4068-A945-87E789863186Q39468421-ECDB59F2-097E-4710-A54D-2FF548B31097Q40107054-23E229D8-F35F-4257-99D0-2F9E06BFC0C6Q40107059-9805D5EC-742A-4BF3-8841-045BAC3F2FB0Q40205686-AAC8916A-E852-4812-B96A-71DD65DDC907Q40474474-1CA48C98-1658-4247-9758-C8E4915F60C1Q41839444-97050C6D-CADC-481B-A1C8-4F3839AFDD8AQ44821407-829B3EBF-4344-42A1-9615-C7B4C69172BEQ47610511-DE0A14E5-A9C8-4BBD-9A7B-DB38A75351ADQ58478863-B9835682-23B4-4252-9686-0EC1138F66E7Q90015591-D89663EA-7907-4669-8EF6-ABEB2C1D908AQ90068199-D57A5AF5-0FEE-4CDE-B66C-284573CBA9A8Q90084004-37CA1F13-64C5-4E95-934D-62744F03BCAAQ90173104-8FC809AE-DF4D-4924-9785-144E0F5A7C65Q90382714-20A3ADC8-61D8-4956-9C1B-BFA2054443C2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dai Wang
@ast
Dai Wang
@en
Dai Wang
@es
Dai Wang
@nl
Dai Wang
@sl
type
label
Dai Wang
@ast
Dai Wang
@en
Dai Wang
@es
Dai Wang
@nl
Dai Wang
@sl
prefLabel
Dai Wang
@ast
Dai Wang
@en
Dai Wang
@es
Dai Wang
@nl
Dai Wang
@sl
P106
P21
P31
P496
0000-0001-5666-8622
P569
2000-01-01T00:00:00Z